Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice. - PubMed - NCBI

Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice. - PubMed - NCBI

Curr Treat Options Gastroenterol. 2019 Nov 18. doi: 10.1007/s11938-019-00267-w. [Epub ahead of print]

Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice.

Stern B1, McGarrity T2, Baker M3.

Author information

1

Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, 200 Campus Dr, Suite 2400|Entrance 4, Hershey, PA, 17033, USA. bstern@pennstatehealth.psu.edu.

2

Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, 200 Campus Dr, Suite 2400|Entrance 4, Hershey, PA, 17033, USA.

3

Division of Hematology Oncology, Penn State Health Milton S. Hershey Medical Center, Penn State Cancer Institute, 400 University Dr, Hershey, PA, 17033, USA.

Abstract

PURPOSE OF REVIEW:

Decades have passed since the underlying molecular etiologies of the most common hereditary forms of colorectal cancer (CRC), Lynch syndrome, and familial adenomatous polyposis (FAP) were first described. With the advent of next-generation sequencing (NGS) panels, the landscape of hereditary CRC testing has changed dramatically. We review available screening strategies, novel CRC predisposition genes, and challenges and opportunities in this field.

RECENT FINDINGS:

Improved sensitivity and availability of NGS panel testing have greatly expanded our understanding regarding the number of CRC syndromes and their phenotypic expression. A variety of screening strategies are available to identify heritable CRC syndromes, potentially decreasing morbidity and mortality in this population. However, these screening strategies remain imperfect and present challenges regarding their implementation in clinical practice. Screening strategies include universal screening of CRC tumors for Lynch syndrome, clinical prediction algorithms, and risk assessment questionnaires. Additionally, there remains a gap in our understanding of the clinical implications of novel gene mutations of variable penetrance and unexpected NGS panel test results. Incorporation of single nucleotide polymorphisms (SNPs) may help to further refine cancer risk assessment, and the clinical introduction of RNA analysis may allow us to clarify variants of unknown significance (VUSs) and identify deep intronic mutations that would otherwise be missed. Recognition of genetic predisposition to CRC is critical for the practicing gastroenterologist. The evolving field of cancer genetics offers great challenges and opportunities for improved CRC management.

KEYWORDS:

Cancer genetic testing; Cancer risk assessment; Genetic counseling; Hereditary colorectal cancer; Next-generation sequencing panel; Polyposis

PMID:

 

31741210

 

DOI:

 

10.1007/s11938-019-00267-w